HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC - supplementary material

Authors
Publication date
20 September 2023
Publisher
Doi

    Abstract

    infographic of: HERTHENA-Lung01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR-Mutated NSCLC</p

      Similar works

      Full text

      thumbnail-image

      Available Versions

      FigShare

      redirect
      oaioai:figshare.com:article/24168...
      Last time updated on 22/09/2023